OrphAI Therapeutics Presents Phase 2a LAM-001 Data at ATS 2026
20 Jan 2026 //
GLOBENEWSWIRE
OrphAI Therapeutics Appoints Dr. Aaron Waxman to Board
19 Feb 2025 //
GLOBENEWSWIRE
OrphAI Therapeutics receives Orphan Drug Designation for AIT-101
15 Feb 2024 //
GLOBENEWSWIRE

Market Place
Sourcing Support